Peak Concentrations of Ustekinumab After IV Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Gastroenterology and Hepatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission
Clin. Gastroenterol. Hepatol. 2021 Jan 01;19(1)111-118.e10, J Hanžel, J Zdovc, T Kurent, N Sever, K Javornik, K Tuta, M Koželj, N Smrekar, G Novak, B Štabuc, E Dreesen, D Thomas, T Vovk, I Grabnar, D DrobneFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.